Apple Tree Partners / AEs / Tokai Pharmaceuticals Inc. / Tokai Pharmaceuticals Tokai Pharmaceuticals / IMMEDIATE RELEASE Tokai Pharmaceuticals / /
Event
FDA Phase / Funding / /
Facility
Dana-Farber Cancer Institute / /
IndustryTerm
food effect / biopharmaceutical / treatment of castration-resistant prostate cancer / /
MedicalCondition
cancers / castration-resistant prostate cancer / seizures / seizure / stable disease / prostate cancer / /
Organization
Harvard Medical School / Novartis Venture Fund / American Society of Clinical Oncology Genitourinary Cancers Symposium / Dana-Farber Cancer Institute / Satter Foundation / /
Person
Taplin / Jodie Morrison / /
Position
driver / co-principal investigator / president and chief executive officer / professor of medicine / director of genitourinary clinical research / associate professor / /
NEWS RELEASE FOR IMMEDIATE RELEASE Tokai Pharmaceuticals’ Reformulated Galeterone Demonstrates Robust PSA Reductions in Advanced Prostate Cancer Patients Interim Results from ARMOR2 Phase 2 Study Presented at 2014 ASC